Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Do we still believe in the dopamine hypothesis? New data bring new evidence.

Abi-Dargham A.

Int J Neuropsychopharmacol. 2004 Mar;7 Suppl 1:S1-5. Review.

PMID:
14972078
2.

Recent evidence for dopamine abnormalities in schizophrenia.

Abi-Dargham A.

Eur Psychiatry. 2002 Aug;17 Suppl 4:341s-347s. Review.

PMID:
23573603
3.

Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited.

Winterer G.

Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S68-71.

PMID:
16508900
4.

[Hallucinations, consciousness and psychosis].

Del Cul A, Gaillard R, Jardri R, Fossati P.

Encephale. 2010 Sep;36(4):348-54. doi: 10.1016/j.encep.2010.07.001. Epub 2010 Aug 19. Review. French. No abstract available.

PMID:
20850607
5.

[Value of brain imaging in assessment of cognitive symptoms. Cognitive and emotional impact of antipsychotic drug treatment]].

Martinot JL, Peretti CS.

Encephale. 2006 Jan;32 Pt 2:S3-5. French. No abstract available.

PMID:
16800076
6.

Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia.

Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, Abi-Dargham A.

JAMA Psychiatry. 2016 Aug 1;73(8):862-70. doi: 10.1001/jamapsychiatry.2016.0178.

7.

[The dopaminergic hypothesis revisited].

Guillin O.

Encephale. 2006 Oct;32(5 Pt 4):S908-11; discussion S912. Review. French. No abstract available.

PMID:
17119503
8.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Arnsten AF, Girgis RR, Gray DL, Mailman RB.

Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Review.

PMID:
26946382
9.

Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Heinz A, Schlagenhauf F.

Schizophr Bull. 2010 May;36(3):472-85. doi: 10.1093/schbul/sbq031. Epub 2010 May 7. Review.

10.
11.

[Deficit schizophrenia: from pharmacology to clinical practice].

Tassin JP.

Encephale. 1996 Jun;22 Spec No 2:9-12. Review. French.

PMID:
8767035
12.

[Distribution and function of dopamine D1, D2 receptor].

Suhara T, Miyoshi M.

Rinsho Shinkeigaku. 2007 Nov;47(11):826-8. Review. Japanese.

PMID:
18210808
13.

[Source monitoring: general presentation and review of literature in schizophrenia].

Ferchiou A, Schürhoff F, Bulzacka E, Mahbouli M, Leboyer M, Szöke A.

Encephale. 2010 Sep;36(4):326-33. doi: 10.1016/j.encep.2009.12.010. Epub 2010 Mar 7. Review. French.

15.

Neurobiology of dopamine in schizophrenia.

Guillin O, Abi-Dargham A, Laruelle M.

Int Rev Neurobiol. 2007;78:1-39. Review.

PMID:
17349856
16.

Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.

Pickar D, Litman RE, Konicki PE, Wolkowitz OM, Breier A.

Mod Probl Pharmacopsychiatry. 1990;24:124-51. Review.

PMID:
1970851
17.

Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia.

Stahl SM.

CNS Spectr. 2007 Apr;12(4):265-8. No abstract available.

PMID:
17426663
18.

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M.

Nature. 1997 Feb 13;385(6617):634-6.

PMID:
9024661
19.

Dopamine in schizophrenia: a review and reconceptualization.

Davis KL, Kahn RS, Ko G, Davidson M.

Am J Psychiatry. 1991 Nov;148(11):1474-86. Review.

PMID:
1681750
20.

An integrated neuropathophysiological model of schizophrenia.

Holden TJ.

Med Hypotheses. 1989 Feb;28(2):109-13.

PMID:
2927352

Supplemental Content

Support Center